In Vitro Assessment of the Allelic Variants of Cytochrome P450
- 1 January 2012
- journal article
- review article
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 27 (1) , 68-84
Abstract
The cytochrome P450 (CYP) superfamily is one of the most important groups of enzymes involved in drug metabolism. It is responsible for the metabolism of a large number of drugs. Many CYP isoforms are expressed polymorphically, and catalytic alterations of allelic variant proteins can affect the metabolic activities of many drugs. The CYP2D6, CYP2C9, CYP2C19, and CYP2B6 genes are particularly polymorphic, whereas CYP1A1, CYP1A2, CYP2E1, and CYP3A4 are relatively well conserved without common functional polymorphisms. In vitro studies using cDNA expression systems are useful tools for evaluating functional alterations of the allelic variants of CYP, particularly for low-frequency alleles. Recombinant CYPs have been successfully expressed in bacteria, yeast, baculoviruses, and several mammalian cells. Determination of CYP variant-mediated kinetic parameters (Km and Vmax) in vitro can be useful for predicting drug dosing and clearance in humans. This review focuses on the advantages and disadvantages of the various cDNA-expression systems used to determine the kinetic parameters for CYP allelic variants, the methods for determining the kinetic parameters, and the findings of in vitro studies on highly polymorphic CYPs, including CYP2D6, CYP2C9, CYP2C19, and CYP2B6.Keywords
This publication has 104 references indexed in Scilit:
- Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial ArtemetherDrug Metabolism and Disposition, 2011
- Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450Toxicological Sciences, 2010
- Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 IsozymesDrug Metabolism and Disposition, 2009
- Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17Drug Metabolism and Disposition, 2007
- Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymesBiochemical and Biophysical Research Communications, 2005
- Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenaseBritish Journal of Clinical Pharmacology, 2002
- CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stabilityBiochemical and Biophysical Research Communications, 2002
- Polymorphic Variants (CYP2C9*3 and CYP2C9*5) and the F114L Active Site Mutation of CYP2C9: Effect on Atypical Kinetic Metabolism ProfilesDrug Metabolism and Disposition, 2002
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Expression of Rat NADPH-Cytochrome P-450 Reductase cDNA in Saccharomyces cerevisiaeDNA, 1986